These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9186343)

  • 21. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
    Joyce R; Fenton MA; Rode P; Constantine M; Gaynes L; Kolvenbag G; DeWolf W; Balk S; Taplin ME; Bubley GJ
    J Urol; 1998 Jan; 159(1):149-53. PubMed ID: 9400459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
    Smith DS; Carvalhal GF; Mager DE; Bullock AD; Catalona WJ
    J Urol; 1998 Nov; 160(5):1734-8. PubMed ID: 9783942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
    Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer.
    Noldus J; Ferrari M; Prestigiacomo A; Stamey TA
    Urology; 1996 May; 47(5):713-8. PubMed ID: 8650871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
    Kelly WK; Scher HI
    J Urol; 1993 Mar; 149(3):607-9. PubMed ID: 7679759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
    Collette L; de Reijke TM; Schröder FH;
    Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of African-American ethnic background with survival in men with metastatic prostate cancer.
    Thompson I; Tangen C; Tolcher A; Crawford E; Eisenberger M; Moinpour C
    J Natl Cancer Inst; 2001 Feb; 93(3):219-25. PubMed ID: 11158191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined finasteride and flutamide therapy in men with advanced prostate cancer.
    Ornstein DK; Rao GS; Johnson B; Charlton ET; Andriole GL
    Urology; 1996 Dec; 48(6):901-5. PubMed ID: 8973674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
    Furuya Y; Nagakawa O; Fuse H
    Urol Int; 2003; 70(3):195-9. PubMed ID: 12660456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
    Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
    Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
    Ornstein DK; Smith DS; Andriole GL
    Urology; 1998 Dec; 52(6):1094-7. PubMed ID: 9836561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
    Fowler JE; Pandey P; Seaver LE; Feliz TP; Braswell NT
    J Urol; 1995 Jun; 153(6):1860-5. PubMed ID: 7538599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.